Reported 1 day ago
On May 14, Jim Cramer discussed Bristol-Myers Squibb (NYSE:BMY), emphasizing its struggles due to an impending patent cliff affecting lucrative drugs. While he noted the company's decent oncology portfolio and a 5.6% dividend yield, he advised caution in buying more stock until they see improvements in its new drug COBENFY, which recently had disappointing study results. Cramer is holding off on additional purchases, expecting the stock may drop further.
Source: YAHOO